Laboratorios Del Dr. Esteve S.a.

Laboratories Del Dr. Esteve S.a.

Laboratorios De Dr. Esteve

Esteve Pharmaceuticals, S.a.

Daniel Zamanillo-Castanedo

José Miguel Vela Hernández

Helmut Heinrich Buschmann

Margarita Puig Riera De Conias

Jose Miguel Vela Hernandez

Bernhard Wünsch

Dirk Schepmann

Jose Miguel Vela-Hernandez

Enrique Portillo-Salido

Carlos-Ramón Plata-Salaman

Xavier Codony-Soler

Sebastià Videla-CÉS

Carlos Plata-Salaman

José-Carlos Prados-Salazar

José-Miguel Vela HERNÁNDEZ

Helmut H Buschmann

Torsten SCHLÄGER

José Miguel Vela-HERNÁNDEZ

Jordi Bruna-escuer

José-Miguel Vela-Hernandez

Christoph Oberdorf

José Manuel Baeyens-Cabrera

Francisco Rafael Nieto-López

José Miguel Vela-Hernández

The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations

The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.

1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

Sigma ligands for use in the prevention and/or treatment of post-operative pain

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

Use of sigma ligands in opioid-induced hyperalgesia

The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs. 

Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery. 

Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Growing community of inventors

Barcelona, Spain

Daniel Zamanillo-Castanedo